{{Drugbox
| IUPAC_name = 2-methyl-5-(methylsulfonylmethyl)-''N''-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]-1,2,4-triazol-3-amine
| image = Sufotidine.svg
| width = 300

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Development terminated
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 80343-63-1
| ATC_prefix = None
| ATC_suffix =  
| PubChem = 71763
| ChemSpiderID = 64802
| UNII = 56B0591Y76
| KEGG = D05939

<!--Chemical data-->
| C=20 | H=31 | N=5 | O=3 | S=1 
| molecular_weight = 421.556 g/mol
| smiles = CN1C(=NC(=N1)CS(=O)(=O)C)NCCCOC2=CC=CC(=C2)CN3CCCCC3
| StdInChI = 1S/C20H31N5O3S/c1-24-20(22-19(23-24)16-29(2,26)27)21-10-7-13-28-18-9-6-8-17(14-18)15-25-11-4-3-5-12-25/h6,8-9,14H,3-5,7,10-13,15-16H2,1-2H3,(H,21,22,23)
| StdInChIKey = JEYKZWRXDALMNG-UHFFFAOYSA-N
}}

'''Sufotidine''' ([[International Nonproprietary Name|INN]],<ref>{{cite web|title=International Nonproprietary Names for Pharmaceutical Substances. Supplement to ''WHO Chronicle'', 1986, Vol. 40, No. 6. Recommended International Nonproprietary Names (Rec. INN): List 26|url=http://www.who.int/medicines/publications/druginformation/innlists/RL26.pdf|publisher=World Health Organization|accessdate=12 January 2016|page=9}}</ref> [[United States Adopted Name|USAN]], codenamed AH25352) is a long-acting competitive [[H2 receptor|H<sub>2</sub> receptor]] [[receptor antagonist|antagonist]] which was under development as an [[Peptic ulcer|antiulcerant]] by Glaxo (now [[GlaxoSmithKline]]).<ref>{{cite web|title=Drug Profile: Sufotidine |url=http://adisinsight.springer.com/drugs/800000594|website=AdisInsight|publisher=Springer International Publishing AG|accessdate=12 January 2016}}</ref> It was planned to be a follow-up compound to [[ranitidine]] (Zantac).<ref>{{cite web|title=Glaxo Plans to Follow Up Zantac with Long-acting Sufotidine; H<sub>2</sub> Antagonist Is One of Seven Drugs Targeted for Worldwide Marketing Applications in 1988–90|url=https://www.pharmamedtechbi.com/publications/the-pink-sheet/49/048/glaxo-plans-to-follow-up-zantac-with-longacting-sufotidine-h2-antagonist-is-one-of-seven-drugs-targeted|website=Pharma & MedTech Business Intelligence|publisher=Informa Business Intelligence, Inc., an Informa Company|accessdate=12 January 2016|date=November 30, 1987}}</ref> When taken in doses of 600&nbsp;mg twice daily it induced virtually 24-hour gastric anacidity<ref>{{cite journal|last1=Smith|first1=JT|last2=Pounder|first2=RE|title=Sufotidine 600 mg bd Virtually Eliminates 24 hour Intragastric Acidity in Duodenal Ulcer Subjects|journal=Gut|date=March 1990|volume=31|issue=3|pages=291–3|pmid=1969833|doi=10.1136/gut.31.3.291|pmc=1378269}}</ref> thus closely resembling the antisecretory effect of the [[proton pump inhibitor]] [[omeprazole]].<ref>{{cite journal|last1=Fiorucci|first1=S|last2=Santucci|first2=L|last3=Farroni|first3=F|last4=Pelli|first4=MA|last5=Morelli|first5=A|title=Effect of Omeprazole on Gastroesophageal Reflux in Barrett's Esophagus|journal=The American Journal of Gastroenterology|date=October 1989|volume=84|issue=10|pages=1263–7|pmid=2801676}}</ref> Its development was terminated in 1989<ref>{{cite book|editor1-last=Ganellin|editor1-first=C.R.|editor2-last=Triggle|editor2-first=D.J.|title=Dictionary of Pharmacological Agents|date=1999|publisher=Chapman & Hall|location=London|isbn=9780412466304|edition=1st}}</ref> from [[Phases of clinical research#Phase III|phase III clinical trials]] based on the appearance of carcinoid tumors in long-term toxicity testing in rodents.<ref>{{cite book|editor1-last=Lawton|editor1-first=G.|editor2-last=Witty|editor2-first=D.R.|title=Progress in Medicinal Chemistry. Vol. 50|date=2011|publisher=Academic|location=London|isbn=978-0-12-381290-2|page=36|edition=1st}}</ref>

==Synthesis==
[[File:Sufotidine synthesis.png|600px|center]]

==See also==
* [[Lavoltidine]] (previously known as loxtidine) — a similar compound in which methyl[[sulfone]] group is replaced with hydroxyl

==References==
{{Reflist}}

{{H2-receptor antagonist}}
{{Histaminergics}}

[[Category:Abandoned drugs]]
[[Category:Amines]]
[[Category:H2 receptor antagonists]]
[[Category:Piperidines]]
[[Category:Triazoles]]
[[Category:Phenol ethers]]
[[Category:Sulfones]]